Results
To determine the cell proliferation potential of BPA, ht-UtLM cells were
exposed to a wide range of ultra-low to low doses (0, 10 −6 ,
10 −5 , 10 −4 , 10 −3 ,
10 −2 , 10 −1 , 1, 10, 100 and 200
μM) of BPA for 24, 48 and 72h. Cell proliferation, measured by an MTS
assay, was significantly increased (P<0.05) in ht-UtLM cells at doses
from 10 −6 (1 pM) to 10 μM at 24, 48 and 72h and
significantly decreased (P<0.05) at doses of 100 μM at 72h, and
200 μM at all time points compared to the cells without BPA exposure, and
formed non-monotonic, inverted U-shaped, curves ( Fig. 1A ). The proliferative responses to BPA were similar to that of
E 2 at 10 −2 μM (a positive control)
( Fig. 1A ).
The percentage of cells in the different phases of the cell cycle were
obtained by flow cytometry to evaluate the effects of BPA on cell cycle
progression in ht-UtLM cells ( Fig. 1B ). It
appears that BPA at concentrations of 10 −6 ,
10 −3 , and 1 μM in ht-UtLM cells remarkably altered
the cell cycle by shifting cells from G 0 -G 1 to S phase
(P<0.005) and increasing the percentage of cells in the S phase, whereas
the number of cells in G 2 -M phase remained unchanged as compared to
controls at 24h ( Fig. 1B ). These data
supported the findings of BPA induced increased proliferation in ht-UtLM cells
(see Fig. 1A ).
The ERα36 gene and protein expression induced by BPA was
determined by real time RT-PCR and immunofluorescence confocal microscopy,
respectively. Total RNA extracted from BPA-treated (10 −3
μM) ht-UtLM cells transfected with siERα36 or siScr fragments was
examined for gene expression levels of ERα36. There was a significant
increase in ERα36 gene expression with fold changes of 3.09, 3.56 and 3.80 detected for cells treated with BPA at 10 −6 ,
10 −3 , and 1 μM, respectively, compared to untreated
controls 0 μM (p<0.05; Fig.
2A ). Additionally, immunofluorescence staining and confocal
microscopy revealed ERα36 protein was predominantly localized to the
cytoplasm. At 24h, following an exposure to 10 −3 μM
BPA, ERα36 expression was significantly increased in the cells compared
to cells without treatment (p<0.001; Fig.
2B ). However, when ERα36 was knocked down by siERα36,
the increased expression of both gene and protein levels of ERα36 were
attenuated. The data confirmed ERα36 expression at the gene and protein
levels is responsive to BPA exposure, and may play a role in BPA induced cell
proliferation of ht-UtLM cells.
To determine the involvement of ERα36 in the ht-UtLM cell
proliferation and cell cycle progression, a silencing RNA technique was applied.
The cells were transfected with siERα36 or siScr fragments then treated
with 10 −3 μM of BPA. The proliferative effect of BPA on
ht-UtLM cells was abolished when the functional ERα36 was knocked down by
siERα36 in cells treated with BPA compared to the cells transfected with
siScr (scrambled RNA fragment) and containing a functional ERα36
(p<0.05; Fig. 3A ). Additionally,
there was an alteration in cell cycle progression when cells were transfected
with siERα36 (P<0.0008), in that the progression effects induced
by BPA were diminished, and S phase remained unchanged ( Fig. 3B ). Therefore, these results further support the
hypothesis that ERα36 is involved in the proliferative effects observed
in ht-UtLM cells induced by BPA.
To determine whether BPA could activate the MAPK pathway through
phosphorylation of protein kinases and receptor tyrosine kinases (RTKs), ht-UtLM
cells were exposed to BPA (0, 10 −6 , 10 −3 , 1
μM) for 10 min, and western blots of cell lysates were probed with
anti-phosphorylated and anti-total Src and EGFR. The cells exposed to BPA were
found to have increased tyrosine phosphorylation of Src and EGFR. Both
phosphorylated protein expression levels were increased significantly in the
siScr transfected cells exposed to BPA compared to the controls without BPA
exposure (p<0.05; Fig. 4A ). However,
phosphorylated Src and EGFR expression levels were attenuated in the cells
transfected with siERα36 when treated with BPA ( Fig. 4A and 4B ), which indicated that BPA could induce
increased expression of ERα36; concurrently the phosphorylation levels of
receptor tyrosine kinase, EGFR and downstream proteins, Src and MAPK were also
increased.
In order to determine the role of ERα36 and receptor-associated
transmembrane signaling molecules in ht-UtLM cells following BPA treatment,
protein expression of downstream MAPK-associated SOS1 and Grb2 signaling
molecules were determined by western blot analysis with or without
siERα36. The data indicated that BPA at 10 −6 ,
10 −3 , 1 μM increased protein expression of
ERα36, SOS1 and Grb2 in ht-UtLM cells as determined by western blotting
and densitometric analysis (p<0.05; Fig.
5A ). However, knockdown of ERα36 gene expression with
siERα36 abolished these effects. The base-line expression of human
hypoxanthine phosphoribosyl transferase (HPRT) was used as a housekeeping
protein.
To investigate whether BPA could mediate MAPK activation, downstream of
SOS1 and Grb2 in ht-UtLM cells, the cells were exposed to BPA (0,
10 −6 , 10 −3 , 1 μM) and evaluated
by western blotting for activation of downstream mediators Ras and
MAPK p44/42 . The data showed that a short exposure period of 10
min to various doses of BPA induced rapid, increased expression of
phosphorylated Ras (pRas) and MAPK p44/42 (pMAPK p44/42 ) in
the cells. Knocking down ERα36 with siERα36 resulted in a
reduction in phosphorylation of Ras and MAPK p44/42 compared with
ht-UtLM cells with siScr exposed to the same amount of BPA ( Fig. 5B ). Densitometric scanning and ratio of
phosphorylated/total protein showed that Ras and MAPK p44/42 followed
similar patterns, and were significantly increased in ht-UtLM cells transfected
with siScr and treated with BPA compared with untreated ht-UtLM cells
(P<0.01–0.05; Fig. 5B ); and
that phosphorylated Ras and MAPK p44/42 levels in ht-UtLM cells
transfected with siERα36 were approximately decreased to the levels seen
in controls without BPA treatment ( Fig.
5B ).
To determine the expression and if there was association of
ERα36, EGFR and phosphorylated Src following BPA exposure with or without
a functional ERα36, ht-UtLM cells were transfected with siScr or
siERα36 and exposed to 10 −3 μM of BPA for 10
min, then analyzed by immunofluorescence confocal microscopy, PLA assay and
coimmunoprecipitation analysis. EGFR has been previously reported to be located
in the mitochondria ( Demory, Boerner, Davidson
et al., 2009 ) and we wanted to assess whether BPA treatment could
facilitate the localization of EGFR to mitochondria. The cells were stained with
DAPI (blue) for nuclei and MitoTracker ( Demory
et al., 2009 ) for mitochondria localization, and a specific primary
antibody was used for staining EGFR ( Fig.
6A ). The data showed increased expression of EGFR and partial
localization in mitochondria when the cells were treated with BPA ( Fig. 6A ). These effects were abolished when
the ERα36 gene was knocked down by siERα36 fragments ( Fig. 6A ). Phospho-Src and ERα36
colocalized together in the cells with more PLA dots/cell in the cells with a
functional ERα36 induced by BPA compared to the control. When
ERα36 gene expression was knocked down by siERα36 fragments, the
increased PLA dots/cell of ERα36 and phospho-Src were diminished ( Fig. 6B ).
To determine if there was an association between increased levels of
phospho-EGFR and phospho-Src, which could initiate MAPK pathway signaling
induced by BPA, an immunoprecipitation technique was applied to pull down
phospho-EGFR with phospho-Src ( Fig. 6C ). We
found that more phospho-EGFR was precipitated with the phospho-Src in cells
treated with BPA compared to cells without BPA treatment with a functional
ERα36 (P < 0.05); however, in cells without a functional
ERα36, the increased coimmunoprecipitation was not seen, which suggests
that pEGFR interacted with pSrc to activate the MAPK pathway, and ERα36
plays an important role in mediating its activation through crosstalk or
independently in the cells treated with BPA.
Materials
Ht-UtLM cells ( Carney, Tahara, Swartz et
al., 2002 ) are hormonally responsive and were used for testing cell
proliferation, functional endpoints, and nongenomic signaling. The cells were
grown and maintained in MEM (Gibco Life Technologies, Grand Island, NY) with
supplements at 37°C, with 95% humidity and 5% CO 2 , as
previously described ( Yu, Saile, Swartz et al.,
2008 ). For the treatment of cells with various concentrations of BPA
(99%; Sigma-Aldrich, Saint Louis, MO) and 17 Beta-estradiol (E 2 )
(Sigma-Aldrich), we used phenol red free DMEM (Gibco Life Technologies) along
with 10% Charcoal Dextran treated FBS (CD-FBS) (GE Healthcare Life Science
Pittsburgh, PA) for preparing test media.
All concentrations for time courses and dose responses were chosen based
on previous studies (2010, Jeng, Kochukov and
Watson, 2010 , Jeng and Watson,
2009 ,Kochukov, Jeng and Watson,
2009 ). The chosen concentrations of BPA reflect the range of
concentrations likely to be found in the environment ( Liao, Liu, Guo et al., 2012 , Liao, Liu, Moon et al., 2012 ). Lower concentrations
are of interest to determine how sensitive biological systems are to presumably
more widespread exposure concentrations. BPA was solubilized in 0.1% DMSO (Sigma
Aldrich) and diluted in treatment medium at required concentrations. A
dose-range of 10 −6 - 200 μM BPA for the cell
proliferation studies, and 10 −6 , 10 −3 , and 1
μM BPA for additional studies was selected.
To evaluate the effects of BPA on cell proliferation, an MTS
(methyltetrazolium sulfate)-based CellTiter 96® Aqueous One Solution Cell
Proliferation Assay (Promega, Madison, WI) was used according to the
manufacturer’s protocol to measure the number of viable cells based on
the dye intensity as previously described ( Gao
et al., 2010 ). Briefly, the ht-UtLM cells were plated in 96-well
plates at 5 × 10 3 cells/well. Ht-UtLM cells were exposed to
BPA at 0, 10 −6 , 10 −5 ,
10 −4 , 10 −3 , 10 −2 ,
10 −1 , 1, 10, 100, and 200 μM and with E 2
at 10 −2 μM as a positive control, along with a vehicle
control (no BPA, but DMSO in culture medium) for 24, 48, and 72h.
Ht-UtLM cells were treated with BPA (10 −6 ,
10 −3 , 1 μM and E 2 ) along with a vehicle
control for 24h for cell cycle analysis. After treatment, cells were fixed with
cold 70% ethanol (overnight) prior to staining with Propidium Iodide (PI). Cells
were examined by flow cytometry using a FACSort Flow Cytometer (San Jose, CA)
equipped with CellQuest Software. An initial gate was set on an PI area versus
width dot-plot to identify single cells and 10,000 single cells collected per
sample. The data was further analyzed using ModFit software to determine each
phase of the cell cycle and are reported as the percentage of G0/G1, S, and G2/M
for each sample.
Real-time RT-PCR was used to determine ERα36 gene expression
induced by BPA. Ht-UtLM cells were treated for 24h with BPA
(10 −6 , 10 −3 μM), or E 2
(10 −2 μM) or untreated. Cells were harvested with
Trizol reagent, and total RNA was extracted with an RNA Purification Kit
(Qiagen, Valencia, CA). Two micrograms of total RNA were used to prepare cDNA
and primed with ERα36 and GAPDH primers (housekeeping gene as control)
and reverse-transcribed with Superscript II (Invitrogen, Carlsbad, CA). The
following primer sets specific for ERα36, forward primer
5’-TTGGAAACAAGTGGTTTCCTCG-3’ and ERα36 reverse primer
5’- CTGCCTCAAAACAAAATGTCCC-3’ and the housekeeping gene GAPDH were
used for gene expression studies. The data analysis was based on the
ΔΔCt method with normalization to GAPDH, and the results were
expressed as fold changes as compared to untreated control groups.
To assess ERα36’s involvement in BPA-induced cell
proliferation, gene expression, and MAPK activation, a short interfering (si)
RNA technique was used to knockdown ERα36 gene expression in ht-UtLM
cells. The ERα36 siRNA fragments were predesigned and produced by Ambion
(catalog# 4399666; hERα36 ID: s499850; Foster City, CA) The transfection
into ht-UtLM cells of siERα36 oligos targeting human ERα36 gene
expression (siERα36) and a control scrambled siRNA (catalog# 4390843;
siScr, Ambion) with a nonsense sequence designed to have no significant sequence
similarity to mouse, rat, or human transcript sequences was done using
Lipofectamine (Invitrogen) as a transfection agent and incubated for 24h
following the manufacturer’s protocol. Transfected ht-UtLM cells with or
without ERα36 silencing (siERα36) were maintained in phenol red
free MEM along with CD-FBS medium containing 0.001% of vehicle (DMSO) for 24h,
then treated with BPA at various concentrations for cell proliferation, cell
cycle and protein expression studies.
Expression levels of ERα36 receptor and associated signaling
proteins were determined in ht-UtLM cells transfected with siERα36 or
siSrc for 24h, then treated with BPA (10 −6 ,
10 −3 , 1 μM) or E 2 for 24h (ERα36,
Grb2 and SOS1 expression studies) and for 10 min (phosphorylated EGFR, Src, Ras
and MAPK p44/42 expression studies) by western blot analysis as
previously described ( Yu et al., 2008 ).
The following primary antibodies were used for the western blotting: Rabbit
Polyclonal Anti-SOS1 and Anti-Grb2 (1:1000 dilution, Cell Signaling Technology
Inc, Danvers, MA); Rabbit Polyclonal Anti-ERα36 (1:1000 dilution, Cell
Applications, Inc., San Diego, CA); Rabbit Polyclonal Anti-HPRT (1:500 dilution,
Santa Cruz Biotechnology Inc., Santa Cruz, CA); Rabbit Polyclonal
Anti-pEGFR(tyr845)/tEGFR, Anti-pSrc(tyr416)/tSrc, Anti-pRas1/tRas1 and
Anti-pMAPK/tMAPK p44/42 (1:1000 dilution, Cell Signaling
Technology). The blots were incubated at 4°C, overnight. Primary
antibodies were detected with horseradish peroxidase-conjugated secondary
anti-rabbit or anti-mouse antibodies by incubating at RT for 1h and followed by
an ECL Western Blotting detection reagent (GE Healthcare, Buchinghamshire,
UK).
Expression of ERα36 in ht-UtLM cells following BPA exposure was
determined by immunofluorescence and confocal microscopy. The cells were grown
on glass bottom plates at a density of 50,000 cells/plate and transfected with
siERα36 or siSrc for 24 h. The cells were then treated with 0 or
10 −3 μM of BPA for 24h. For immunofluorescence
staining, ht-UtLM cells were fixed in −20°C methanol for 5 min,
and blocked with 10% normal goat serum for 30 min on ice. The cells were
incubated with primary antibody of ERα36 (1:100 dilution, Cell
Applications Inc., San Diego, CA) in 1.5% normal goat serum overnight. The
secondary antibody of Alexa Fluor 488 goat anti-rabbit (Invitrogen) was used at
1:3000 dilution for 1h at RT, followed by 3 μM DAPI (Molecular Probes,
Eugene, OR) for nuclear staining for 30 min. For negative controls, the cells
were incubated with nonimmune rabbit serum (Jackson Immunoresearch, West Grove,
PA) at the primary antibody’s concentration.
BPA-induced migration of EGFR to mitochondria in cells was also
evaluated. Ht-UtLM cells were grown and transfected with siERα36 or siScr
as described above; then treated with BPA at 10 −3 μM.
The cells were co-stained with a rabbit polyclonal anti-EGFR (Santa Cruz
Biotechnology Inc.) at a 1:50 dilution, and MitoTracker dye (Thermo Fisher
Scientific, Waltham, MA) at 25 nM at 4°C overnight. The cells were
costained with Alexa Fluor 488 goat anti-mouse IgG Antibody and/or Alexa Fluor
594 goat anti-Rabbit IgG antibody at a dilution of 1:3000 for 1h. Cells were
then counterstained with 3 μM DAPI for 30 min. Confocal images were taken
on a Zeiss LSM710-UV (Carl Zeiss Inc, Oberkochen, Germany) using a
Plan-Apochromat 63X/1.40 oil DIC M27 objective. The staining intensity was
measured by ImageJ.
Interaction of intermediary proteins of the MAPK signaling pathway with
ERα36 was assessed by determining the colocalization of activated Src, an
intracellular tyrosine-protein kinase, with ERα36 was measure by PLA
(Sigma, DUO92101–1KT) according to manufacturer’s protocol.
Briefly, the ht-UTLM cells were grown on glass bottom plates until 70% of
confluent and transfected with siERα36 or siSrc for 24 h, treated with 0
or 10 −3 μM of BPA for 10min, fixed with 4% of
paraformaldehyde for 20min, and permeabilized with 0.1% triton X-100 for 30min.
The cells then were incubated with a rabbit polyclonal anti-ERα36 (Cell
Application) at a 1:100 dilution and a mouse monoclonal anti-phospho-Src
(tyr416) antibody (Millipore, Temecula, CA) at a 1:50 dilution, overnight at
4° C. The cells were only incubated with pSrc antibody in negative
control plate). PLUS and MINUS secondary PLA probes against rabbit and mouse IgG
were added with incubation at 37° C for 1h, followed by incubation with
ligase for 30 min at 37° C. Amplification was then applied for 120 min at
37° C. The coverslips were mounted on plate with Doulink Mounting Medium
with Dapi (Sigma, DUO82040). The cells were imaged on a Zeiss LSM780-UV (Carl
Zeiss Inc, Oberkochen, Germany) using a Plan-Apochromat 40X/1.40 oil DIC M27
objective. The number of PLA dots ( Bustosa V et
al., 2017 ) was measured by Fiji.
To detect the association of phospho-EGFR(tyr845) with
phospho-Src(tyr416), an immunoprecipitation Kit–dynabeads Protein G
(ThermoFisher Scientific, Waltham, MA) was used. A total of 500 μg of
total protein from cell lysate in different conditions (see western blot analysis ) was mixed with 500 μl of
binding buffer. The 50 μl of Dynabeads® Protein G was incubated
with 10 μg of phospho-Src mouse monoclonal antibody (Merck Millipore,
Burlington, MA) for 30 min at RT. The Dynabeads-Ab complex was then resuspended
with the cell lysate and incubated on a rotation rocker at RT for 2h. The
Dynabeads-Ab-Antigen complexes were washed and eluted according to the
manufacturer’s instructions, separated on SDS-PAGE, and analyzed by
western blotting with anti-phospho-EGFR (Cell Signaling) and anti-phospho-Src
(Merck Millipore).
Nonparametric tests were used to perform statistical analyses. The
Mann-Whitney Exact test ( Conover, 1995 )
was used to compare proliferation and western blot band intensities between
treated and untreated. The Mann-Whitney Exact test was also used to compare
treated to untreated for staining intensities. The student T-test was used to
analyze PLA dots/cell between treated and un treated groups. For the real-time
RT-PCR studies, statistical analyses were performed on the normalized values
with housekeeping genes using the ΔΔCt method. All data are
displayed with standard error of the mean calculated from independent
experiments.
Discussion
BPA is present ubiquitously in the environment and in human tissues due to
its widespread use ( Gao et al., 2015 ). The
structural and functional similarity of BPA to that of estrogen substantiates
BPA’s xenoestrogenic potential. Transplacental exposures to BPA causes
alterations of the gene expression profiles in E 2 -sensitive tissues of
rats, particularly ovary and uterus ( Naciff, Jump,
Torontali et al., 2002 ). Neonatal exposures in mice have been found to
produce uterine tumors, such as leiomyomas, later in life ( Newbold, Jefferson and Padilla-Banks, 2009 ). In our
study, we found BPA induced increased proliferation of human uterine leiomyoma cells
that was well comparable to that of E 2 , and provided evidence that BPA is
a xenoestrogen that influences leiomyoma cell growth at very low levels. The
proliferative responses observed were within a dose-range of pico- to micromolar
concentrations in vitro, which is well within the recommended human
(children/adult) exposure range ( Richter et al.,
2007 , Wetherill et al., 2007 ,2010).
Our findings are also consistent with other groups that have reported BPA exposures
target cell types in the uterus and can induce pathologic changes such as
adenomyosis, leiomyoma, atypical hyperplasia, and stromal polyps in rodents at human
exposure levels ( Newbold et al., 2007 ). BPA
also stimulates proliferation in human breast cancer cells ( Wu, Wei and Hao, 2009 ); therefore, BPA is a xenoestrogen
that may impact human health at environmentally relevant concentrations.
BPA also remarkably altered cell cycle progression in this study by
significantly increasing the percentage of cells in the S phase (DNA synthesis)
while decreasing those in G 0 -G 1 phase in BPA-treated ht-UtLM
cells compared to controls. BPA, like E 2 , also promotes cell
proliferation and DNA synthesis in ER-positive ovarian, prostate, and endometrial
cancer cells ( Liu, Xu, Yin et al., 2010 ).
Likewise, BPA-mediated cell entry into S phase implies the triggering of DNA
replication that promotes the cell proliferation observed in leiomyoma cells in the
present study.
Rapid responses to E 2 and E 2 -BSA are seen in
ERα-negative HCC38 and ERα-positive MCF-7 breast cancer cells ( Boyan, Sylvia, Frambach et al., 2003 ). Blockers
of ERα/ERβ ICI 182780 failed to inhibit BPA mediated proliferative
responses in human normal breast cells and in ER negative breast cancer cells ( Wu, Wei, Jiang et al., 2012 ), which suggests
that besides conventional ERs, alternative membrane-associated receptor mediated
rapid signaling pathways may operate in both BPA and E 2 induced cell
proliferation ( Wetherill et al., 2007 ). There
are several publications that state BPA, at or below human exposure levels
(10 −12 to 10 −7 M), stimulates proliferation
of human testicular JKT-1 cells via a nongenomic action that is independent of
classical ERs ( Bouskine, Nebout, Brucker-Davis et
al., 2009 ). Another alternative nongenomic signaling pathway is the G
protein-coupled estrogen receptor (GPR30 or GPER) found in ER-positive and
ER-negative breast cancer cells ( Filardo, Quinn,
Pang et al., 2007 ). It is proposed that the ERα36 and GPR30
nongenomic pathways are integrated in that it has been suggested that the GPR30
nongenomic signaling pathway activation of pERK1/2 is directly mediated by
ERα36, and not by GPR30, because the activities of GPR30 promoted by
E 2 are due to induction of ERα36 expression ( Kang, Guo, Zhang et al., 2011 ). In addition to the above
observations, which prompted us to look at ERα36, BPA’s binding
affinity to ERα and β is a thousand-times lower than E 2
( Gao et al., 2015 , Kuiper et al., 1998 ,2010); http://lib.znate.ru/docs/index-20398.html?page=47 ). A variety of
signaling pathways from the cell membrane to the nucleus may be driving BPA-mediated
leiomyoma cell proliferation. Several studies have shown that cell proliferation
induced by BPA in human breast cancer cells is through signaling ( Lee, Hwang, Park et al., 2012 ) via ERα
membrane-associated receptors and/or nongenomic pathways ( Wu et al., 2012 ).
ERα36 is a variant of ERα66 first identified and cloned by
Wang’s group in 2005 ( Wang, Zhang, Shen et
al., 2005 ). ERα36 is located on the plasma membrane and within the
cytoplasm, although there has been controversy as to its exact subcellular
localization. We have found that ERα36 is mostly in mitochondria as we have
observed significant Pearson’s correlation coefficients for colocalization of
ERα36 with mitochondria by confocal microscopy in ht-UtLM cells, and also
uterine smooth muscle cells ( Yan, Yu, Castro et al.,
2017 ). It is proposed that ERα36 functions as a mediator of rapid
membrane-initiated, nongenomic, signal-regulated, kinase mitogenic signaling pathway
(2010, Chaudhri et al., 2012 , Wang et al., 2006 , Wang et al., 2005 , Gu,
Chen, Lopez et al., 2014 , Lin, Yan, Liang
et al., 2009 ). In the present study, low doses of BPA significantly
induced gene and protein expression of ERα36 and triggered entry of cells
into S phase, and promoted cell proliferation suggesting a nongenomic pathway
triggering that led to activation of mitogenic signaling molecules and initiation of
cell proliferation.
The elevated level of ERα36 gene and protein expression in BPA
treated ht-UtLM cells has driven us to knockdown ERα36 gene expression to
observe the effects of BPA on ht-UtLM cells without a functional ERα36. As
expected, the promotion of cell proliferation and cell cycle progression induced by
BPA was abrogated, which strongly suggests the involvement of ERα36 in the
BPA’s mitogenic effects in ht-UtLM cells. To further examine the effects of
BPA on nongenomic signaling at concentrations relevant to human exposure levels,
ht-UtLM cells with or without a functional ERα36 were used to identify the
predominant ERα36 signaling proteins through which BPA initiated nongenomic
signaling. We found increased expression of ERα36 in leiomyoma cells and
associated increased expression of intermediary proteins, SOS1 and Grb2, in cells,
which suggested a coordinated induction and activation of intracellular signaling
molecules involved in Ras-ERK/MAP kinase signaling as seen in this study and
observed in our previous studies with other xenoestrogens ( Di, Yu, Moore et al., 2008 ). Thus, our findings of BPA
mediated initiation and triggering of rapid transmembrane signaling via ERα36
and induction of intracellular signaling molecules provides evidence for nongenomic
actions of BPA in leiomyoma cells. Our conclusions were further strengthened by the
fact that these signaling molecules were significantly increased and/or activated in
BPA-treated cells that had a functional ERα36 compared to untreated control
cells, or cells where the functional ERα36 was silenced, and these effects
were abrogated. Together, these observations would suggest that the nongenomic MAPK
signaling pathway was activated, and contributed to the enhanced cell proliferation
and cell cycle progression caused by BPA exposure; and that ERα36 played an
important role in initiating MAPK signaling through the intracellular molecules SOS1
and Grb2.
The thought of what mediator or mediators bridged the ERα36 and MAPK
pathway activation motivated us to further examine whether ERα36 mediated
nongenomic MAPK pathway activation was though the activation of receptor tyrosine
kinases (RTKs) via Src phosphorylation. The Src (proto-oncogene c-Src) is a
non-receptor tyrosine kinase whose expression and activity has led to a diverse
array of biological functions including proliferation, cell growth, differentiation,
cell shape, motility, migration, angiogenesis, and survival ( Wheeler, Iida and Dunn, 2009 ). The Src protein contains
multiple domains for specific attachment to membranes ( Kaplan, Varmus and Bishop, 1990 ). Several investigators
discovered a significant coexpression of ERα36 and epidermal growth factor
receptor (EGFR) in primary breast cancers, suggesting that ERα36 took part in
EGFR-related carcinogenesis (2010, Su, Xu, Li et al.,
2014 , Vranic, Gatalica, Deng et al.,
2011 ). A positive feedback loop was confirmed that EGFR signaling
activated transcription of ERα36 through an activator-protein-1-binding site
in the promoter of ERα36. In turn, ERα36 interacted with the EGFR/Src
complex to strengthen the EGFR signaling pathway and stabilize EGFR protein ( Zhang, Kang, Ding et al., 2011 ). It has also
been reported that EGFR, Src and ERα36 could be located in mitochondria
(2010, Demory et al., 2009 , Yan et al., 2017 , Hebert-Chatelain, 2013 ), and Src could function as a switch in
ERα36-mediated mitogenic signaling through EGFR phosphorylation in
ER-negative breast cancer cells ( Zhang, Ding, Kang
et al., 2012 ). In the present study, BPA induced transmembrane
ERα36 receptor expression and increased Src and EGFR phosphorylation, which
indicated that ERα36 plays an integral positive role in rapid nongenomic
signaling in leiomyoma cell proliferation, and this all may be mediated through the
activation of EGFR through Src phosphorylation. Activation of Scr/EGFR leads to the
signaling cascade of Ras-ERK/MAP kinases ( Yu, Moore
and Dixon, 2010 , McKay and Morrison,
2007 ). Activated EGFR could interact with the adapter protein, SH2. The
SH2-containing collagen-related proteins (Shc) and the growth-factor-receptor
binding protein Grb2 initiate signaling via Ras and MAP kinase ( Li, Batzer, Daly et al., 1993 , Rozakis-Adcock, Fernley, Wade et al., 1993 ). A Grb2-SOS1
interaction provides a key regulatory mediator that relays signaling from activated
RTKs to the downstream effector molecules particularly Ras. Thus, low-dose BPA
mediated multiple signaling pathways that originate at the cell membrane by
interacting with the membrane / cytosolic ERα36 concurrent with the EGFR and
its downstream target and associated proteins and protein complexes to initiate
rapid signaling that converges in the nucleus for transcription of proliferation
factors and possibly tumor promotion. The colocalization of ERα36 and
phosphorylated Src observed by PLA ( Bustosa et al.,
2017 ) further provides evidence of a bridge role of Src in ERα36
mediated EGFR/MAPK signaling and pathway activation induced by BPA.
Conclusions
The results of this study demonstrate that the interaction of BPA with the
membrane / cytosolic ERα36 receptor presumably is through its ligand binding
domain. BPA concurrently activates EGFR through Src phosphorylation, which in turn
upregulates associated signaling complexes including the molecules SOS1, Grb2, and
Ras that lead to activation of downstream effector MAPK p44/42 resulting
in leiomyoma cell cycle progression by inducing cell entry into the S phase from
G0-G1 phase leading to cell proliferation ( Fig.
7 ). Thus, ERα36 appears to play a pivotal role in BPA-induced MAPK
signaling. Human exposure to environmental concentrations of BPA and at its
recommended human exposure levels may be an inducer of hormonally responsive
reproductive tract tumors including uterine fibroids, implying as a risk factor for
humans.
Introduction
BPA is recognized as an environmental estrogen and a proven endocrine
disrupting chemical (EDC) both in vivo and in
vitro ( Gao, Yang, Li et al.,
2015 , Peretz, Vrooman, Ricke et al.,
2014 , Richter, Birnbaum, Farabollini et
al., 2007 ) BPA is pervasive and is found in dust, air, and paper currency
and receipts. It is present in human serum, urine, amniotic fluid, and breast milk
in the populations of industrialized countries worldwide. In a reference population
of 394 adults in the United States, BPA was detected in 95% of human urine samples
with a median concentration of 1.28 μg/L (5.6 nM) and in human serum at
levels of 0.2–1.6 ng/mL (0.88–7.0 nM) ( Gao et al., 2015 ). Therefore, due to ubiquitous exposures of populations
to BPA, it is a public health concern ( Gao et al.,
2015 , Peretz et al., 2014 ).
BPA is structurally and functionally similar to 17β-estradiol
(E 2 ), has estrogenic effects, and interacts differentially with
estrogen receptors alpha (ERα) and beta (ERβ) ( Ashby and Odum, 2004 ), but has 2,000–10,000-fold
lower binding affinity to classical ERs than E 2 ( Kuiper, Lemmen, and Carlsson et al., 1998 ). BPA has also
been shown to elicit rapid, nongenomic estrogenic responses via nonclassical
membrane-anchored ERs ( Wetherill, Akingbemi, and
Kanno et al., 2007 ), such as the transmembrane G protein-coupled
receptor, GPR30 (GPER) ( Dong, Terasaka and Kiyama,
2011 ). Another membrane-associated ER and a variant of ERα66, is
the truncated ERα36, which is an estrogen-responsive receptor that can
activate crosstalk among multiple pathways involved in proliferation, cell survival
(anti-apoptotic), and metastatic events in breast cancer (2010, Chaudhri, Olivares-Navarrete, Cuenca et al., 2012 , Wang, Zhang, Shen et al., 2006 ). Also,
ERα36 has been implicated in estrogen-stimulated MAPK (ERK) activation ( Wang et al., 2006 ). BPA at low concentrations
is reported to increase proliferation and phosphorylation of MAPK in ER-negative
breast cancer cells (2010, Song, Zhang, Yang et al.,
2015 , Zhang, Wang, Liu et al.,
2015 ).
At human exposure levels, BPA induced uterine leiomyomas in adult mice
following neonatal exposures ( Newbold, Jefferson and
Padilla-Banks, 2007 ). Also, it was reported that human leiomyoma tissue
concentrations of BPA were significantly higher than that of myometrial tissue
( Othman, Al-Adly, Elgamal et al., 2016 ).
However, the specific molecular mechanisms of BPA’s action on
estrogen-responsive uterine leiomyomas in women are not yet known. Due to
BPA’s ubiquitous nature and wide-spread human exposures, in addition to its
estrogenic activity, ability to induce uterine leiomyomas in mice, and the hormonal
dependency of uterine leiomyomas in women, our immortalized human uterine leiomyoma
(ht-UtLM; fibroid) cells were used to evaluate the low-dose effects of this
xenoestrogen ( Gao, Yu, Castro et al.,
2010 , Watson, Bulayeva, Wozniak et al.,
2005 , Yu, Moore, Castro et al.,
2012 ). The present study was therefore, designed to determine the rapid
nongenomic mechanisms of action of low doses of BPA at human exposure levels, in
human fibroid cells, and to evaluate whether BPA’s effects are mediated via
the transmembrane receptor, ERα36.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.